Rhythm Pharmaceuticals (RYTM) Q1 2026 earnings review
Global Revenue Hits Record While Launch Costs Deepen Losses
Rhythm broke records with a 59% YoY jump in total revenue to $60.1M, but the composition shifted dramatically. U.S. sales reversed direction, dropping 5% sequentially due to Q1 insurance plan transitions and specialty pharmacy inventory drawdowns. This headwind was completely masked by a 27% QoQ surge in international sales. Meanwhile, the bottom line deteriorated as net loss widened to $56.7M. The 62% YoY surge in SG&A expenses highlights the massive investment required to fund the newly approved U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). The company is well-capitalized with $340M, but execution on the HO launch must be flawless to justify the burn.
🐂 Bull Case
FDA approval for acquired HO on March 19 unlocks an estimated 10,000 U.S. patients. Over 150 patient start forms were received in just six weeks, proving immediate pent-up demand.
Ex-U.S. revenue surged 27% sequentially to $23.2M. The May 1st European Commission Marketing Authorization for acquired HO sets the stage for a lucrative EU rollout in 2027.
🐻 Bear Case
U.S. sales declined sequentially. While blamed on Q1 insurance bridging and inventory timing, relying on lumpy ex-U.S. orders to drive growth is a fragile dynamic.
The Phase 3 EMANATE trial failed entirely in March. This severely limits label expansion into genetic MC4R pathway diseases, placing immense pressure on the HO indication to deliver.
⚖️ Verdict: ⚪
Neutral. The international revenue acceleration is impressive and the early HO launch metrics are promising. However, the EMANATE trial failure, U.S. revenue drop, and accelerating cash burn warrant a cautious stance until the U.S. HO launch proves it can drive sustainable, highly profitable growth.
Key Themes
U.S. Revenue Reversing as Ex-U.S. Accelerates
A major divergence appeared in Q1. U.S. product revenue reversed course, declining 5% QoQ to $36.9M. Management blamed specialty pharmacy inventory dynamics and patients utilizing free-drug bridging programs during Q1 insurance plan transitions. This weakness was entirely bailed out by Ex-U.S. revenue, which accelerated 27% QoQ to $23.2M. Historically, international sales are lumpy, making this a concerning dynamic if U.S. demand doesn't rebound quickly.
Acquired HO Launch Shows Immediate Traction
The March 19 FDA approval for acquired HO is Rhythm's most significant catalyst, unlocking a concentrated market of highly motivated, already-diagnosed patients. The receipt of over 150 start forms in the first six weeks validates management's thesis that this launch curve will be faster and steeper than the foundational Bardet-Biedl syndrome (BBS) launch.
EMANATE Trial Failure Concentrates Risk
The March 16 announcement that the Phase 3 EMANATE trial failed all four independent substudies is a significant blow. While management pointed to positive post-hoc signals in SRC1 and POMC, failing the primary endpoints strips away near-term label expansion opportunities for genetically caused MC4R pathway diseases. The company's growth story is now almost entirely dependent on the commercial execution of the HO launch.
Operating Expenses Accelerating Heavily
SG&A expenses accelerated rapidly to $63.6M, representing a massive 62% YoY increase. This spike was driven by expanded headcount and marketing to support the HO launch. R&D also ticked up 12% YoY to $41.7M. Rhythm is spending aggressively to capture market share, meaning the top line must maintain high-double-digit growth to prevent cash runway concerns from emerging over the next 12-18 months.
Next-Generation Pipeline Progressing
With EMANATE failing, the spotlight shifts to Rhythm's life-cycle management. Management successfully completed an End-of-Phase-2 meeting for bivamelagon in acquired HO and plans to initiate a pivotal Phase 3 trial by year-end 2026. The weekly injectable RM-718 is on track for a mid-year 2026 data readout. Shifting patients from daily to weekly or oral formulations is critical for long-term franchise durability.
Other KPIs
Declining from $388.9M at the end of 2025. The company burned approximately $48.3M in the quarter. Management maintains that this position is sufficient to fund operations for at least 24 months, carrying them into 2028. This provides an adequate buffer to navigate the critical first phase of the HO launch without immediate dilution risk.
Accelerating slightly. Up from $37.0M a year ago. The increase was driven by rising headcount costs, partially offset by a net decrease in chemistry, manufacturing, and controls (CMC) costs. This figure will likely remain elevated as the company readies the Phase 3 trial for bivamelagon.
Guidance
Stable. The company maintained its aggressive full-year spending plan, which excludes stock-based compensation. This represents a roughly 35% increase over FY25's $295.5M Non-GAAP OpEx. Management expects the spend to be heavily weighted toward next-gen molecule development (30%), the U.S. HO launch (25%), and Japanese commercial build-out (15%).
Stable. Maintained from prior guidance. With $63.6M already spent in Q1, the implied run rate for the remaining three quarters is approximately $43M to $46M per quarter, suggesting that Q1 absorbed a disproportionate amount of upfront launch costs.
Stable. Maintained from prior guidance. With $41.7M spent in Q1, the company is tracking slightly below the implied quarterly run rate needed to hit the midpoint, leaving dry powder for the RM-718 trials and the initiation of the bivamelagon Phase 3 trial later this year.
Key Questions
U.S. Demand Normalization
You cited specialty pharmacy inventory and free-drug bridging as the primary culprits for the 5% QoQ U.S. revenue decline. Has this dynamic normalized in Q2, and can we expect U.S. sequential growth to resume immediately?
HO Launch Conversion Metrics
You received 150 patient start forms for HO in the first six weeks. Given the high price point and prior authorization hurdles, what is the expected time from start form to a paid, dispensed script for this specific population?
EMANATE Failure Read-Through
With the Phase 3 EMANATE trial failing to hit its primary endpoints, what specifically went wrong with the trial design or underlying biology, and how does this alter your broader strategy for the MC4R pipeline beyond HO and BBS?